
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL is positioning itself as a leader in the multi-cancer early detection (MCED) space with their Galleri blood test, which has already shown promising results in clinical trials, including a 14% reduction in Stage IV cancer incidence and a 60% positive predictive value. The upcoming FDA approval for Galleri, as well as Medicare reimbursement, have the potential to unlock a substantial market opportunity for GRAIL. While there are concerns around adoption rates and cash burn, GRAIL's strong clinical performance and potential for international expansion make it a compelling investment opportunity.
Bears say
GRAIL is a healthcare company focused on developing technologies for early cancer detection. Despite its promising multi-cancer early detection blood test, the company faces several challenges that may hinder its growth potential. These include a slower-than-expected ramp-up in test volumes, potential structural constraints on the adoption curve, and potential cost headwinds from resumed royalty payments to Illumina. While GRAIL has a compelling clinical asset and upcoming FDA catalyst, its stock may be overvalued given these risks and the competitive landscape of the healthcare industry.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares